These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 21692668)
1. The rise of antimicrobial resistance: a clear and present danger. Holmes NE; Howden BP Expert Rev Anti Infect Ther; 2011 Jun; 9(6):645-8. PubMed ID: 21692668 [TBL] [Abstract][Full Text] [Related]
2. Factors associated with recovery of multidrug-resistant bacteria in a combat support hospital in Iraq. Aldous WK; Co EM Infect Control Hosp Epidemiol; 2010 Apr; 31(4):425-7. PubMed ID: 20184421 [No Abstract] [Full Text] [Related]
3. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS; Jones RN; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [TBL] [Abstract][Full Text] [Related]
4. Is there any rationale for treatment of Staphylococcus aureus infections with antimicrobials that are determined to be ineffective in vitro? Uekötter A; Peters G; Becker K Clin Microbiol Infect; 2011 Aug; 17(8):1142-7. PubMed ID: 21672081 [TBL] [Abstract][Full Text] [Related]
5. The current state of multidrug-resistant gram-negative bacilli in North America. Nicasio AM; Kuti JL; Nicolau DP Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992 [TBL] [Abstract][Full Text] [Related]
7. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876 [TBL] [Abstract][Full Text] [Related]
8. Activity of topical antimicrobial agents against multidrug-resistant bacteria recovered from burn patients. Glasser JS; Guymon CH; Mende K; Wolf SE; Hospenthal DR; Murray CK Burns; 2010 Dec; 36(8):1172-84. PubMed ID: 20542641 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Rossolini GM; Mantengoli E Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126 [TBL] [Abstract][Full Text] [Related]
11. Emerging resistance in Gram-negative pathogens and implications for clinical practice. Cantón R; Lumb J Future Microbiol; 2011 Jan; 6(1):19-22. PubMed ID: 21162632 [TBL] [Abstract][Full Text] [Related]